Phase 4
Completed N=7
Predicting Inflammatory Skin Disease Response to IL-23 Blockade
Source: ClinicalTrials.gov NCT04541329 ↗Enrolled (actual)
7
Serious AEs
0.0%
Results posted
Apr 2024
Primary outcomePrimary: Psoriasis Area and Severity Index (PASI) Score — 3.9 score on a scale
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
This study examines the effect of IL-23 blockade with Tildrakizumab on the immune cells of psoriatic skin lesions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Psoriasis Area and Severity Index (PASI) Score |
3.9 | — |
Eligibility Criteria
Inclusion Criteria
- Male or female ≥18 years of age at clinic visit.
- Documentation of moderate-severe psoriasis or atypical psoriasis.
- Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.
Exclusion Criteria
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data
- Tuberculosis, active serious infection, active systemic malignancy,
- Received a systemic medication for psoriasis within 3 months of study screening
Data sourced from ClinicalTrials.gov (NCT04541329). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.